Inhibrx (NASDAQ:INBX - Get Free Report) released its quarterly earnings data on Monday. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21), Zacks reports. The company had revenue of $0.10 million for the quarter.
Inhibrx Price Performance
Shares of NASDAQ:INBX traded up $0.25 during trading hours on Friday, hitting $14.35. The stock had a trading volume of 118,160 shares, compared to its average volume of 215,034. The stock's fifty day simple moving average is $13.27 and its 200 day simple moving average is $14.65. Inhibrx has a 1-year low of $10.80 and a 1-year high of $35.42.
Analyst Ratings Changes
Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
View Our Latest Analysis on INBX
About Inhibrx
(
Get Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
